Back to search
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Acute Leukemia
Clinicaltrials.gov:
EU CTIS:
#2023-506581-31-00
J&J ID:
#CR108998
Other:
#75276617ALE1001
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Acute Leukemia
Trial type
Interventional
Trial phase
Phase 1
Investigational
product
product
Bleximenib
Age
2+ years old
Biological sex
All
Placebo?
No
Trial start date
May 19, 2021
Trial end date
September 22, 2030
CT.gov ID
#NCT04811560
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Australia,
- Belgium,
- Brazil,
- Canada,
- China,
- France,
- Israel,
- Japan,
- South Korea,
- Spain,
- Taiwan,
- United Kingdom,
- United States
Loading...
Enrolling
Seoul, South Korea, 05505
Enrolling
Dallas, Texas, United States, 75246
Enrolling
Vandœuvre-lès-Nancy, France, 54511
Enrolling
Vandœuvre-lès-Nancy, France, 54500
Enrolling
Tours, France, 37044
Enrolling
Pierre-Bénite, France, 69310
Enrolling
Nantes, France, 44093
Enrolling
Haifa, Israel, 3436212
Enrolling
Taichung, Taiwan, 404327
Enrolling
Duarte, California, United States, 91010
Enrolling
Pamplona, Spain, 31008
Enrolling
Boston, Massachusetts, United States, 02115
Enrolling
Hangzhou, China, 310009
Enrolling
Philadelphia, Pennsylvania, United States, 19111
Enrolling
São Paulo, Brazil, 01509 900
Enrolling
São Paulo, Brazil, 01246 000
Enrolling
Ghent, Belgium, 9000
Enrolling
Southport, Australia, 4211
Enrolling
Villejuif, France, 94805
Enrolling
London, United Kingdom, SE1 9RT
Enrolling
Jerusalem, Israel, 9112001
Enrolling
Zhengzhou, China, 450003
Enrolling
Besançon, France, 25000
Enrolling
Montreal, Quebec, Canada, H1T 2M4
Enrolling
Paris, France, 75010
Enrolling
Paris, France, 75012
Enrolling
Barcelona, Spain, 08036
Enrolling
Salamanca, Spain, 37007
Enrolling
Madrid, Spain, 28040
Enrolling
Barcelona, Spain, 08035
Enrolling
Valencia, Spain, 46010
Enrolling
Madrid, Spain, 28007
Enrolling
Seville, Spain, 41013
Enrolling
Madrid, Spain, 28009
Enrolling
Houston, Texas, United States, 77030-2740
Enrolling
Strasbourg, France, 67098
Enrolling
Marseille, France, 13009
Enrolling
Toulouse, France, 31059
Enrolling
Tianjin, China, 301609
Enrolling
Brasília, Brazil, 70390 700
Enrolling
São Paulo, Brazil, 01401 002
Enrolling
Leeds, United Kingdom, LS9 7TF
Enrolling
Natal, Brazil, 59062 000
Enrolling
Houston, Texas, United States, 77030
Enrolling
Providence, Rhode Island, United States, 02903
Enrolling
Boston, Massachusetts, United States, 02114
Enrolling
Milwaukee, Wisconsin, United States, 53226
Enrolling
Rio de Janeiro, Brazil, 20230 130
Enrolling
Clayton, Australia, 3168
Enrolling
The Bronx, New York, United States, 10467
Enrolling
New York, New York, United States, 10016
Enrolling
Guangzhou, China, 510515
Enrolling
Tainan, Taiwan, 704
Enrolling
Taipei, Taiwan, 10043
Enrolling
Portland, Oregon, United States, 97239
Enrolling
Oxfordshire, United Kingdom, OX3 7LE
Enrolling
Beijing, China, 100034
Enrolling
Toronto, Ontario, Canada, M5G 1X6
Enrolling
Jinan, China, 250012
Enrolling
Buffalo, New York, United States, 14263
Enrolling
Perth, Australia, 6000
Enrolling
Seoul, South Korea, 06351
Enrolling
San Antonio, Texas, United States, 78229
Enrolling
Seoul, South Korea, 03080
Enrolling
Ramat Gan, Israel, 52621
Enrolling
Indianapolis, Indiana, United States, 46237
Enrolling
Grand Rapids, Michigan, United States, 49546
Enrolling
Seattle, Washington, United States, 98104
Enrolling
Tel Aviv, Israel, 6423906
Enrolling
Manchester, United Kingdom, M20 4BX
Enrolling
Liverpool, United Kingdom, L7 8YA
Enrolling
Nanchang, China, 330006
Enrolling
Wenzhou, China, 325000
Enrolling
Changchun, China, 130021
Enrolling
San Francisco, California, United States, 94158
Enrolling
Wuhan, China, 430022
Enrolling
London, United Kingdom, W1T 7HA
Enrolling
Cardiff, United Kingdom, CF14 4XW
Enrolling
Plymouth, United Kingdom, PL6 8DH
Enrolling
San Francisco, California, United States, 94143
Enrolling
Chicago, Illinois, United States, 60637
Enrolling
Albuquerque, New Mexico, United States, 87131
Enrolling
Knoxville, Tennessee, United States, 37920
Enrolling
Vancouver, British Columbia, Canada, V5Z 1M9
Enrolling
Richmond, Virginia, United States, 23298
Enrolling
Chengdu, China, 610041
Enrolling
Yamagata, Japan, 990 2331
Enrolling
Nanjing, China, 210009
Enrollment complete
Fukushima, Japan, 960 1295
Enrollment complete
Maebashi, Japan, 371-0821
Enrollment complete
Sapporo, Japan, 060-8648
Enrollment complete
Kanazawa, Japan, 920 8641
Enrollment complete
Kobe, Japan, 650 0047
Enrollment complete
Fukuoka, Japan, 812-0054
Enrollment complete
Tokyo, Japan, 141-8625
Enrollment complete
Kashiwa, Japan, 277-8577
Completed
Pessac, France, 33604
Completed
Detroit, Michigan, United States, 48201 2013
Completed
Nagoya, Japan, 466-8560
Completed
Louisville, Kentucky, United States, 40207
Completed
Orange, California, United States, 92868
Completed
Yoshida, Japan, 910-1193
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
